Minimally invasive disc injection reduces pain and improves function in chronic back pain, feasibility study finds

VIVEX Biologics, Inc. sponsored research reports positive outcomes for patients with chronic lumbar discogenic pain treated using a single intradiscal injection of VIA Disc NP, an allogeneic nucleus pulposus product derived from cadaveric disc tissue. Researchers conducted a prospective, single-arm clinical study at six U.S. sites to assess the impact of intradiscal injection of VIA Disc NP on back pain severity and functional impairment in patients with chronic lumbar discogenic pain unresponsive to conservative management. A total of 28 adults were enrolled, with 22 participants completing the 12-month follow-up. Patients received a single injection of 100 mg of VIA Disc...